CD69 Expression on Peripheral CD4+ T Cells Parallels Disease Activity and Is Reduced by Mycophenolate Mofetil Therapy in Uveitis
To assess the effects of mycophenolate mofetil (MMF) therapy on T helper cell activation status, using CD69 expression and cytokine profile with flow cytometry in relation to clinical activity in uveitis. Patients with posterior or intermediate uveitis treated with MMF (n = 10), patients with active...
Gespeichert in:
| Veröffentlicht in: | Investigative ophthalmology & visual science 2001-05, Vol.42 (6), p.1285-1292 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1292 |
|---|---|
| container_issue | 6 |
| container_start_page | 1285 |
| container_title | Investigative ophthalmology & visual science |
| container_volume | 42 |
| creator | Kilmartin, Dara J Fletcher, Zoe J Almeida, Julie A Liversidge, Janet Forrester, John V Dick, Andrew D |
| description | To assess the effects of mycophenolate mofetil (MMF) therapy on T helper cell activation status, using CD69 expression and cytokine profile with flow cytometry in relation to clinical activity in uveitis.
Patients with posterior or intermediate uveitis treated with MMF (n = 10), patients with active uveitis not treated with MMF and receiving no or minimal therapy (n = 10), and healthy volunteers (n = 21) had peripheral blood lymphocyte immunofluorescence analysis for T helper cell (CD4, CD3) markers, activation status (CD69), and intracellular cytokine (interleukin [IL]-2, interferon [IFN]-gamma, and IL-4) levels. Patients were compared before and during MMF therapy in relation to T helper cell activation and clinical activity.
Patients with active uveitis not treated with MMF and receiving no or minimal therapy had increased frequency of CD69-positive CD4 T cells (10.5% +/- 4.6%, P = 0.0007) compared with healthy volunteers (3.3% +/- 2.7%). Of all patients receiving MMF therapy, only patients with moderate to severe uveitis activity in the pre-MMF treatment group (n = 5; 15.5% +/- 5.0%, P = 0.004) had increased frequency of CD69-positive CD4 T cells compared with healthy volunteers. During MMF therapy, a significant reduction in frequency of CD69-positive CD4 T cells occurred in patients with prior moderate to severe uveitis activity (to 8.9% +/- 3.8%, P = 0.04). Levels of CD69-positive CD4 T cells in patients who had had inactive or mildly active disease (n = 5) before and during MMF therapy were comparable with levels in healthy volunteers. No significant changes in cytokine levels were found between the patient and control groups. A significant association between changes in frequency of CD69-positive CD4 T cells and changes in visual acuity (P = 0.008) and changes in vitreal haze (binocular indirect ophthalmoscopy score; P = 0.01) was observed in MMF-treated patients with prior moderate to severe uveitis activity.
Reduction in uveitis activity during MMF therapy correlates with reduction in frequency of peripheral blood CD69-positive CD4 cells. The frequency of CD69-positive CD4 T cells is a measure of activity in posterior uveitis and may guide adequate immunosuppression. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70808194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70808194</sourcerecordid><originalsourceid>FETCH-LOGICAL-h266t-647a32778bfbfee01836a1af58cd59af0785e7616371474974b9bb4e5c5634db3</originalsourceid><addsrcrecordid>eNpFkNtKw0AQhoMotlZfQRYEbySwm-wplyX1UGixSHsdNsnErGwOZtPG3PnorlgVBmYYPr5h_hNvShgLfCZkeOpNMaHcxxTTiXdh7RvGASEBPvcmhISBFJRMvc94wSN0_9F2YK1uauRqA51uS-iUQfGC3qEtisEYizbKrQy4aaEtKAtonvX6oPsRqTpHS4teIN9nkKN0ROsxa5ykbozqAa2bAnpt0PZb245I12h3AN1re-mdFcpYuDr2mbd7uN_GT_7q-XEZz1d-GXDe-5wKFQZCyLRICwBMZMgVUQWTWc4iVWAhGQhOeCgIFTQSNI3SlALLGA9pnoYz7_bH23bN-x5sn1TaZu4vVUOzt4nAEksSUQdeH8F9WkGetJ2uVDcmv5k54OYIKJspU3SqzrT94yJJKSb_90r9Wg66g8RWLj0nJckwDDRIeEICycIvAc6CFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70808194</pqid></control><display><type>article</type><title>CD69 Expression on Peripheral CD4+ T Cells Parallels Disease Activity and Is Reduced by Mycophenolate Mofetil Therapy in Uveitis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kilmartin, Dara J ; Fletcher, Zoe J ; Almeida, Julie A ; Liversidge, Janet ; Forrester, John V ; Dick, Andrew D</creator><creatorcontrib>Kilmartin, Dara J ; Fletcher, Zoe J ; Almeida, Julie A ; Liversidge, Janet ; Forrester, John V ; Dick, Andrew D</creatorcontrib><description>To assess the effects of mycophenolate mofetil (MMF) therapy on T helper cell activation status, using CD69 expression and cytokine profile with flow cytometry in relation to clinical activity in uveitis.
Patients with posterior or intermediate uveitis treated with MMF (n = 10), patients with active uveitis not treated with MMF and receiving no or minimal therapy (n = 10), and healthy volunteers (n = 21) had peripheral blood lymphocyte immunofluorescence analysis for T helper cell (CD4, CD3) markers, activation status (CD69), and intracellular cytokine (interleukin [IL]-2, interferon [IFN]-gamma, and IL-4) levels. Patients were compared before and during MMF therapy in relation to T helper cell activation and clinical activity.
Patients with active uveitis not treated with MMF and receiving no or minimal therapy had increased frequency of CD69-positive CD4 T cells (10.5% +/- 4.6%, P = 0.0007) compared with healthy volunteers (3.3% +/- 2.7%). Of all patients receiving MMF therapy, only patients with moderate to severe uveitis activity in the pre-MMF treatment group (n = 5; 15.5% +/- 5.0%, P = 0.004) had increased frequency of CD69-positive CD4 T cells compared with healthy volunteers. During MMF therapy, a significant reduction in frequency of CD69-positive CD4 T cells occurred in patients with prior moderate to severe uveitis activity (to 8.9% +/- 3.8%, P = 0.04). Levels of CD69-positive CD4 T cells in patients who had had inactive or mildly active disease (n = 5) before and during MMF therapy were comparable with levels in healthy volunteers. No significant changes in cytokine levels were found between the patient and control groups. A significant association between changes in frequency of CD69-positive CD4 T cells and changes in visual acuity (P = 0.008) and changes in vitreal haze (binocular indirect ophthalmoscopy score; P = 0.01) was observed in MMF-treated patients with prior moderate to severe uveitis activity.
Reduction in uveitis activity during MMF therapy correlates with reduction in frequency of peripheral blood CD69-positive CD4 cells. The frequency of CD69-positive CD4 T cells is a measure of activity in posterior uveitis and may guide adequate immunosuppression.</description><identifier>ISSN: 0146-0404</identifier><identifier>EISSN: 1552-5783</identifier><identifier>PMID: 11328741</identifier><identifier>CODEN: IOVSDA</identifier><language>eng</language><publisher>Rockville, MD: ARVO</publisher><subject>Adult ; Antigens, CD - metabolism ; Antigens, Differentiation, T-Lymphocyte - metabolism ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - immunology ; Eye ; Flow Cytometry ; Humans ; Immunosuppressive Agents - therapeutic use ; Interferon-gamma - metabolism ; Interleukins - metabolism ; Lectins, C-Type ; Lymphocyte Activation ; Medical sciences ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - therapeutic use ; Pharmacology. Drug treatments ; Uveitis, Intermediate - drug therapy ; Uveitis, Intermediate - immunology ; Uveitis, Posterior - drug therapy ; Uveitis, Posterior - immunology</subject><ispartof>Investigative ophthalmology & visual science, 2001-05, Vol.42 (6), p.1285-1292</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=984401$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11328741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kilmartin, Dara J</creatorcontrib><creatorcontrib>Fletcher, Zoe J</creatorcontrib><creatorcontrib>Almeida, Julie A</creatorcontrib><creatorcontrib>Liversidge, Janet</creatorcontrib><creatorcontrib>Forrester, John V</creatorcontrib><creatorcontrib>Dick, Andrew D</creatorcontrib><title>CD69 Expression on Peripheral CD4+ T Cells Parallels Disease Activity and Is Reduced by Mycophenolate Mofetil Therapy in Uveitis</title><title>Investigative ophthalmology & visual science</title><addtitle>Invest Ophthalmol Vis Sci</addtitle><description>To assess the effects of mycophenolate mofetil (MMF) therapy on T helper cell activation status, using CD69 expression and cytokine profile with flow cytometry in relation to clinical activity in uveitis.
Patients with posterior or intermediate uveitis treated with MMF (n = 10), patients with active uveitis not treated with MMF and receiving no or minimal therapy (n = 10), and healthy volunteers (n = 21) had peripheral blood lymphocyte immunofluorescence analysis for T helper cell (CD4, CD3) markers, activation status (CD69), and intracellular cytokine (interleukin [IL]-2, interferon [IFN]-gamma, and IL-4) levels. Patients were compared before and during MMF therapy in relation to T helper cell activation and clinical activity.
Patients with active uveitis not treated with MMF and receiving no or minimal therapy had increased frequency of CD69-positive CD4 T cells (10.5% +/- 4.6%, P = 0.0007) compared with healthy volunteers (3.3% +/- 2.7%). Of all patients receiving MMF therapy, only patients with moderate to severe uveitis activity in the pre-MMF treatment group (n = 5; 15.5% +/- 5.0%, P = 0.004) had increased frequency of CD69-positive CD4 T cells compared with healthy volunteers. During MMF therapy, a significant reduction in frequency of CD69-positive CD4 T cells occurred in patients with prior moderate to severe uveitis activity (to 8.9% +/- 3.8%, P = 0.04). Levels of CD69-positive CD4 T cells in patients who had had inactive or mildly active disease (n = 5) before and during MMF therapy were comparable with levels in healthy volunteers. No significant changes in cytokine levels were found between the patient and control groups. A significant association between changes in frequency of CD69-positive CD4 T cells and changes in visual acuity (P = 0.008) and changes in vitreal haze (binocular indirect ophthalmoscopy score; P = 0.01) was observed in MMF-treated patients with prior moderate to severe uveitis activity.
Reduction in uveitis activity during MMF therapy correlates with reduction in frequency of peripheral blood CD69-positive CD4 cells. The frequency of CD69-positive CD4 T cells is a measure of activity in posterior uveitis and may guide adequate immunosuppression.</description><subject>Adult</subject><subject>Antigens, CD - metabolism</subject><subject>Antigens, Differentiation, T-Lymphocyte - metabolism</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>Eye</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon-gamma - metabolism</subject><subject>Interleukins - metabolism</subject><subject>Lectins, C-Type</subject><subject>Lymphocyte Activation</subject><subject>Medical sciences</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Uveitis, Intermediate - drug therapy</subject><subject>Uveitis, Intermediate - immunology</subject><subject>Uveitis, Posterior - drug therapy</subject><subject>Uveitis, Posterior - immunology</subject><issn>0146-0404</issn><issn>1552-5783</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkNtKw0AQhoMotlZfQRYEbySwm-wplyX1UGixSHsdNsnErGwOZtPG3PnorlgVBmYYPr5h_hNvShgLfCZkeOpNMaHcxxTTiXdh7RvGASEBPvcmhISBFJRMvc94wSN0_9F2YK1uauRqA51uS-iUQfGC3qEtisEYizbKrQy4aaEtKAtonvX6oPsRqTpHS4teIN9nkKN0ROsxa5ykbozqAa2bAnpt0PZb245I12h3AN1re-mdFcpYuDr2mbd7uN_GT_7q-XEZz1d-GXDe-5wKFQZCyLRICwBMZMgVUQWTWc4iVWAhGQhOeCgIFTQSNI3SlALLGA9pnoYz7_bH23bN-x5sn1TaZu4vVUOzt4nAEksSUQdeH8F9WkGetJ2uVDcmv5k54OYIKJspU3SqzrT94yJJKSb_90r9Wg66g8RWLj0nJckwDDRIeEICycIvAc6CFw</recordid><startdate>20010501</startdate><enddate>20010501</enddate><creator>Kilmartin, Dara J</creator><creator>Fletcher, Zoe J</creator><creator>Almeida, Julie A</creator><creator>Liversidge, Janet</creator><creator>Forrester, John V</creator><creator>Dick, Andrew D</creator><general>ARVO</general><general>Association for Research in Vision and Ophtalmology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010501</creationdate><title>CD69 Expression on Peripheral CD4+ T Cells Parallels Disease Activity and Is Reduced by Mycophenolate Mofetil Therapy in Uveitis</title><author>Kilmartin, Dara J ; Fletcher, Zoe J ; Almeida, Julie A ; Liversidge, Janet ; Forrester, John V ; Dick, Andrew D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h266t-647a32778bfbfee01836a1af58cd59af0785e7616371474974b9bb4e5c5634db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Antigens, CD - metabolism</topic><topic>Antigens, Differentiation, T-Lymphocyte - metabolism</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>Eye</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon-gamma - metabolism</topic><topic>Interleukins - metabolism</topic><topic>Lectins, C-Type</topic><topic>Lymphocyte Activation</topic><topic>Medical sciences</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Uveitis, Intermediate - drug therapy</topic><topic>Uveitis, Intermediate - immunology</topic><topic>Uveitis, Posterior - drug therapy</topic><topic>Uveitis, Posterior - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kilmartin, Dara J</creatorcontrib><creatorcontrib>Fletcher, Zoe J</creatorcontrib><creatorcontrib>Almeida, Julie A</creatorcontrib><creatorcontrib>Liversidge, Janet</creatorcontrib><creatorcontrib>Forrester, John V</creatorcontrib><creatorcontrib>Dick, Andrew D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Investigative ophthalmology & visual science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kilmartin, Dara J</au><au>Fletcher, Zoe J</au><au>Almeida, Julie A</au><au>Liversidge, Janet</au><au>Forrester, John V</au><au>Dick, Andrew D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD69 Expression on Peripheral CD4+ T Cells Parallels Disease Activity and Is Reduced by Mycophenolate Mofetil Therapy in Uveitis</atitle><jtitle>Investigative ophthalmology & visual science</jtitle><addtitle>Invest Ophthalmol Vis Sci</addtitle><date>2001-05-01</date><risdate>2001</risdate><volume>42</volume><issue>6</issue><spage>1285</spage><epage>1292</epage><pages>1285-1292</pages><issn>0146-0404</issn><eissn>1552-5783</eissn><coden>IOVSDA</coden><abstract>To assess the effects of mycophenolate mofetil (MMF) therapy on T helper cell activation status, using CD69 expression and cytokine profile with flow cytometry in relation to clinical activity in uveitis.
Patients with posterior or intermediate uveitis treated with MMF (n = 10), patients with active uveitis not treated with MMF and receiving no or minimal therapy (n = 10), and healthy volunteers (n = 21) had peripheral blood lymphocyte immunofluorescence analysis for T helper cell (CD4, CD3) markers, activation status (CD69), and intracellular cytokine (interleukin [IL]-2, interferon [IFN]-gamma, and IL-4) levels. Patients were compared before and during MMF therapy in relation to T helper cell activation and clinical activity.
Patients with active uveitis not treated with MMF and receiving no or minimal therapy had increased frequency of CD69-positive CD4 T cells (10.5% +/- 4.6%, P = 0.0007) compared with healthy volunteers (3.3% +/- 2.7%). Of all patients receiving MMF therapy, only patients with moderate to severe uveitis activity in the pre-MMF treatment group (n = 5; 15.5% +/- 5.0%, P = 0.004) had increased frequency of CD69-positive CD4 T cells compared with healthy volunteers. During MMF therapy, a significant reduction in frequency of CD69-positive CD4 T cells occurred in patients with prior moderate to severe uveitis activity (to 8.9% +/- 3.8%, P = 0.04). Levels of CD69-positive CD4 T cells in patients who had had inactive or mildly active disease (n = 5) before and during MMF therapy were comparable with levels in healthy volunteers. No significant changes in cytokine levels were found between the patient and control groups. A significant association between changes in frequency of CD69-positive CD4 T cells and changes in visual acuity (P = 0.008) and changes in vitreal haze (binocular indirect ophthalmoscopy score; P = 0.01) was observed in MMF-treated patients with prior moderate to severe uveitis activity.
Reduction in uveitis activity during MMF therapy correlates with reduction in frequency of peripheral blood CD69-positive CD4 cells. The frequency of CD69-positive CD4 T cells is a measure of activity in posterior uveitis and may guide adequate immunosuppression.</abstract><cop>Rockville, MD</cop><pub>ARVO</pub><pmid>11328741</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-0404 |
| ispartof | Investigative ophthalmology & visual science, 2001-05, Vol.42 (6), p.1285-1292 |
| issn | 0146-0404 1552-5783 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70808194 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Antigens, CD - metabolism Antigens, Differentiation, T-Lymphocyte - metabolism Biological and medical sciences CD4-Positive T-Lymphocytes - immunology Eye Flow Cytometry Humans Immunosuppressive Agents - therapeutic use Interferon-gamma - metabolism Interleukins - metabolism Lectins, C-Type Lymphocyte Activation Medical sciences Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Pharmacology. Drug treatments Uveitis, Intermediate - drug therapy Uveitis, Intermediate - immunology Uveitis, Posterior - drug therapy Uveitis, Posterior - immunology |
| title | CD69 Expression on Peripheral CD4+ T Cells Parallels Disease Activity and Is Reduced by Mycophenolate Mofetil Therapy in Uveitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T01%3A40%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD69%20Expression%20on%20Peripheral%20CD4+%20T%20Cells%20Parallels%20Disease%20Activity%20and%20Is%20Reduced%20by%20Mycophenolate%20Mofetil%20Therapy%20in%20Uveitis&rft.jtitle=Investigative%20ophthalmology%20&%20visual%20science&rft.au=Kilmartin,%20Dara%20J&rft.date=2001-05-01&rft.volume=42&rft.issue=6&rft.spage=1285&rft.epage=1292&rft.pages=1285-1292&rft.issn=0146-0404&rft.eissn=1552-5783&rft.coden=IOVSDA&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70808194%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70808194&rft_id=info:pmid/11328741&rfr_iscdi=true |